2-Bromo-6-nitrotoluene | CAS:55289-35-5

We serve 2-Bromo-6-nitrotoluene CAS:55289-35-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Bromo-6-nitrotoluene

Chemical Name:2-Bromo-6-nitrotoluene
CAS.NO:55289-35-5
Synonyms:2-Bromo-6-nitrotoluene
1-Bromo-2-methyl-3-nitrobenzene
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 259.6±20.0 °C at 760 mmHg
Melting Point 38-40 °C(lit.)
Molecular Formula C7H6BrNO2
Molecular Weight 216.032
Flash Point 110.8±21.8 °C
Vapour Pressure 0.0±0.5 mmHg at 25°C
Index of Refraction 1.593
 MSDS
 
Specification:
Appearance:Yellowish crystalline powder or liquid
Assay:≥98.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2-Bromo-6-nitrotoluene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Bromo-2-methyl-3-nitrobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Bromo-6-nitrotoluene Use and application,2-Bromo-6-nitrotoluene technical grade,usp/ep/jp grade.


Related News: To date, eight cases have been confirmed in the US: three people in California, two in Illinois and one individual each in Massachusetts, Washington State, and Arizona.ethyl (2S)-2-acetamido-3-(1H-indol-3-yl)propanoate manufacturer To date, eight cases have been confirmed in the US: three people in California, two in Illinois and one individual each in Massachusetts, Washington State, and Arizona.10-bromo-2-phenyl-9-(4-phenylphenyl)anthracene supplier People who have returned to the UK from Wuhan in China are being told to stay in for 14 days, and to “self-isolate”.2,6-Dichlorobenzoxazole vendor People who have returned to the UK from Wuhan in China are being told to stay in for 14 days, and to “self-isolate”.As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.